Development of bactericidal antibody during Branhamella catarrhalis infection
- PMID: 3921623
- DOI: 10.1093/infdis/151.5.878
Development of bactericidal antibody during Branhamella catarrhalis infection
Abstract
The recent observation that Branhamella catarrhalis may cause a variety of infections in humans has stimulated interest in human host defenses against this organism. We encountered 21 patients with B. catarrhalis infection: seven with pneumonia, 13 with a purulent exacerbation of chronic bronchitis, and one with purulent sinusitis. Normal human serum (NHS) demonstrated no bactericidal activity against 20 of the 21 isolates. In contrast, 7 of 19 acute and 18 of 20 convalescent sera demonstrated significant bactericidal effects against the corresponding B. catarrhalis isolate. Heating convalescent sera to 56 C for 30 min abolished bactericidal activity. This activity was restored by NHS but not by complement-rich guinea pig serum. Selective blockage of the classic complement pathway eliminated bactericidal activity, whereas selective blockage of the alternative pathway did not. IgG isolated from convalescent serum plus NHS was bactericidal for the corresponding B. catarrhalis isolate. These results suggest that most patients with pulmonary infections due to B. catarrhalis develop a convalescent IgG antibody response that mediates serum bactericidal activity by the classic complement pathway.
Similar articles
-
Branhamella catarrhalis: an organism gaining respect as a pathogen.Clin Microbiol Rev. 1990 Oct;3(4):293-320. doi: 10.1128/CMR.3.4.293. Clin Microbiol Rev. 1990. PMID: 2121328 Free PMC article. Review.
-
Serum antibody response to outer membrane proteins of Moraxella (Branhamella) catarrhalis in patients with bronchopulmonary infection.Clin Diagn Lab Immunol. 1996 Nov;3(6):717-21. doi: 10.1128/cdli.3.6.717-721.1996. Clin Diagn Lab Immunol. 1996. PMID: 8914764 Free PMC article.
-
Immunoglobulin G (IgG) serological response to Branhamella catarrhalis in patients with acute bronchopulmonary infections.J Clin Pathol. 1988 Mar;41(3):329-33. doi: 10.1136/jcp.41.3.329. J Clin Pathol. 1988. PMID: 3129454 Free PMC article.
-
Antibody response to P-protein in patients with Branhamella catarrhalis infections.Am J Med. 1990 May 14;88(5A):25S-27S. doi: 10.1016/0002-9343(90)90257-e. Am J Med. 1990. PMID: 2111089
-
Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen.J Med Microbiol. 1997 May;46(5):360-71. doi: 10.1099/00222615-46-5-360. J Med Microbiol. 1997. PMID: 9152030 Review.
Cited by
-
Incidence of Branhamella catarrhalis in the sputa of patients with chronic lung disease.Drugs. 1986;31 Suppl 3:103-8. doi: 10.2165/00003495-198600313-00022. Drugs. 1986. PMID: 3488188
-
Branhamella catarrhalis: an organism gaining respect as a pathogen.Clin Microbiol Rev. 1990 Oct;3(4):293-320. doi: 10.1128/CMR.3.4.293. Clin Microbiol Rev. 1990. PMID: 2121328 Free PMC article. Review.
-
Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):219-34. doi: 10.1007/BF01699978. Eur J Clin Microbiol Infect Dis. 1998. PMID: 9707304 Review.
-
Serum antibody response to outer membrane proteins of Moraxella (Branhamella) catarrhalis in patients with bronchopulmonary infection.Clin Diagn Lab Immunol. 1996 Nov;3(6):717-21. doi: 10.1128/cdli.3.6.717-721.1996. Clin Diagn Lab Immunol. 1996. PMID: 8914764 Free PMC article.
-
Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.Infect Immun. 1996 Jun;64(6):1900-5. doi: 10.1128/iai.64.6.1900-1905.1996. Infect Immun. 1996. PMID: 8675285 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
